- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Iterum Therapeutics PLC (ITRM)
Iterum Therapeutics PLC stock price live, this page displays NASDAQ ITRM stock exchange data. View the ITRM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Iterum Therapeutics PLC real time stock price chart below.
What Is the Iterum Therapeutics PLC Stock Price Today?
The Iterum Therapeutics PLC stock price today is 0.759.
What Is the Stock Symbol for Iterum Therapeutics PLC?
The stock symbol for Iterum Therapeutics PLC is ""ITRM.""
What Stock Exchange Does Iterum Therapeutics PLC Trade On?
Iterum Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Iterum Therapeutics PLC a Good Stock to Buy?
Determining whether Iterum Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ITRM quote. (ISIN: IE000TTOOBX0)
What Is the Iterum Therapeutics PLC Stock Price Today?
The Iterum Therapeutics PLC stock price today is 0.759.
What Is the Stock Symbol for Iterum Therapeutics PLC?
The stock symbol for Iterum Therapeutics PLC is ""ITRM.""
What Stock Exchange Does Iterum Therapeutics PLC Trade On?
Iterum Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Iterum Therapeutics PLC a Good Stock to Buy?
Determining whether Iterum Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ITRM quote. (ISIN: IE000TTOOBX0)
NASDAQ
Currency in USD
0.759
-0.021(-2.74%)
Real-time Data·
Fair Value
An estimate of a Iterum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.750
0.800
52 wk Range
0.750
3.020
ITRM Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Trading near 52-week Low
More Info
Fair Value
An estimate of a Iterum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7500.800
52 wk Range
0.7503.020
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ITRM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Iterum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
7.000
Upside
+822.27%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Iterum Therapeutics PLC Company Profile
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics PLC Earnings Call Summary for Q4/2024
- Q4 EPS of -$0.12 beats forecast of -$0.22, stock surges 4.7% to $1.56 in pre-market trading
- FDA approval of Orlynypa positions Iterum in $40M annual UTI prescription market
- Q4 net loss narrows to $6.6M, total operating expenses down to $3.7M from $11.4M YoY
- Cash position of $24.1M as of Dec 2024; company exploring partnerships and capital raising options
- Revenue forecast to grow to $2.04M by Q4 2025; analyst price targets range from $5 to $10
Last Updated: 07/02/2025, 15:00
Read Full TranscriptCompare ITRM to Peers and Sector
Metrics to compare | ITRM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipITRMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −5.4x | −0.5x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | −11.9x | 2.9x | 2.6x | |
Price / LTM Sales | - | 2.0x | 3.2x | |
Upside (Analyst Target) | - | 84.8% | 41.2% | |
Fair Value Upside | Unlock | 11.5% | 6.2% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.000
(+822.27% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.10 / -0.15
Revenue / Forecast
-- / 2.68M
People Also Watch
FAQ
What Stock Exchange Does Iterum Therapeutics Trade On?
Iterum Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Iterum Therapeutics?
The stock symbol for Iterum Therapeutics is "ITRM."
What Is the Iterum Therapeutics Market Cap?
As of today, Iterum Therapeutics market cap is 30.32M.
What Is Iterum Therapeutics's Earnings Per Share (TTM)?
The Iterum Therapeutics EPS (TTM) is -0.93.
When Is the Next Iterum Therapeutics Earnings Date?
Iterum Therapeutics will release its next earnings report on 07 Aug 2025.
From a Technical Analysis Perspective, Is ITRM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Iterum Therapeutics Stock Split?
Iterum Therapeutics has split 1 times.
How Many Employees Does Iterum Therapeutics Have?
Iterum Therapeutics has 9 employees.
What is the current trading status of Iterum Therapeutics (ITRM)?
As of 29 Jul 2025, Iterum Therapeutics (ITRM) is trading at a price of 0.76, with a previous close of 0.78. The stock has fluctuated within a day range of 0.75 to 0.80, while its 52-week range spans from 0.75 to 3.02.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.